Dec. 4 at 10:12 AM
$PXMD Based on the 10-Q document, PAXMEDICA, Inc. is a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (APTs) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders like autism spectrum disorder (ASD) to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID-19 Syndrome. https://beyondspx.com/article/paxmedica-inc-pxmd-a-promising-biopharmaceutical-company-navigating-challenges